The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Janssen; MSD; Novartis; Roche
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); Agios (Inst); Amgen (Inst); Argenx (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Eisai (Inst); Exelixis (Inst); FORMA Therapeutics (Inst); GamaMabs Pharma (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Gortec (Inst); H3 Biomedicine (Inst); Incyte (Inst); Innate Pharma (Inst); Institut de Recherches Internationales Servier (Inst); Janssen (Inst); Kura Oncology (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Loxo (Inst); Lytix Biopharma (Inst); MedImmune (Inst); Menarini (Inst); Merus (Inst); MSD (Inst); Nanobiotix (Inst); Nektar (Inst); Novartis (Inst); Octimet (Inst); Oncoethix (Inst); Oncopeptides (Inst); Orion (Inst); Pfizer (Inst); PharmaMar (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst); Sierra Oncology (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); The Lymphoma Academic Research Organization (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - MSD
Other Relationship - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen-Cilag; Johnson & Johnson; Lilly; MedImmune; Merck; NH TherAguix; Novartis; Pfizer; Roche; Sanofi
Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC).
 
Marie-Anne Damiette Smit
No Relationships to Disclose
 
Hossein Borghaei
Honoraria - Axiom Biotechnologies; Bristol-Myers Squibb; Celgene
Consulting or Advisory Role - Abbvie; AstraZeneca; BioNTech; Boehringer Ingelheim; Bristol-Myers Squibb; Cantargia AB; Celgene; EMD Serono; Genentech; Genmab; Lilly; Merck; Novartis; Pfizer; Regeneron; Trovagene
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Lilly; Merck; Novartis
Other Relationship - Takeda; University of Pennsylvania
 
Taofeek Kunle Owonikoko
Stock and Other Ownership Interests - CAMBIUM MEDICAL TECHNOLOGIES
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; EMD Serono; G1 Therapeutics; Lilly; Lilly; MedImmune; Novartis; PharmaMar; Sandoz; Seagen; Takeda
Speakers' Bureau - Abbvie
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Corvus Pharmaceuticals; G1 Therapeutics (Inst); Novartis (Inst); Regeneron (Inst); Stem CentRx (Inst); United Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst)
Other Relationship - Roche/Genentech
 
Horst-Dieter Hummel
Travel, Accommodations, Expenses - Boehringer Ingelheim; Johnson & Johnson
 
Melissa Lynne Johnson
Consulting or Advisory Role - Araxes Pharma (Inst); Astellas Pharma (I); AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Incyte (Inst); Loxo (Inst); Merck (Inst); Mersana (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Otsuka (I); Pfizer (Inst); Ribon Therapeutics (Inst); Sanofi (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BeiGene (Inst); BerGenBio (Inst); Birdie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Checkpoint Therapeutics (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Foundation Medicine (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Hengrui Pharmaceutical (Inst); Incyte (Inst); Janssen (Inst); Kadmon (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Neovia Oncology (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Sanofi (Inst); Stem CentRx (Inst); Syndax (Inst); Syndax (Inst); Tarveda Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo; EMD Serono; Exelixis; Genentech; Incyte; Merck; Pfizer; Sysmex; Vapotherm
 
Stéphane Champiat
No Relationships to Disclose
 
Ravi Salgia
No Relationships to Disclose
 
Hibiki Udagawa
Honoraria - Abbvie; Amco; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim
Research Funding - Abbvie; Amgen; Daiichi Sankyo; MSD
 
Michael J. Boyer
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst)
Research Funding - Amgen (Inst); Ascentage Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Benitec Biopharma (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); OncoMed (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Merck Sharp & Dohme
 
Ramaswamy Govindan
Honoraria - Abbvie; Genentech; Janssen; Millennium; Roche
Consulting or Advisory Role - Abbvie; Adaptimmune; AstraZeneca; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech; GlaxoSmithKline; Inivata; Lilly; Merck; Nektar; Pfizer; Phillips Gilmore Oncology; Roche